Amidst Healthcare Chaos, California Authorizes a New Bill for Diabetes Prevention
Diabetes is rampant in the United States and places an increasing burden on the U.S. healthcare system. In California, 9 percent of adults suffer from diabetes and more than half of the state’s population is considered prediabetic. Within the next five years, almost 70 percent of the prediabetes population is predicted to become diabetic. These are frightening numbers and California has recognized the severity of this epidemic at a time when U.S. lawmakers are debating whether to repeal and/or replace the ACA (Affordable Care Act). California, where the ACA is highly popular and has widespread support, continues to buck the national trend. State officials recently passed a bill that will enroll Medi-Cal recipients in a diabetes prevention program. These programs, starting in July of 2018, will encourage patients with prediabetes to exercise, eat healthy, and reduce stress, with a goal of helping them to lose between 5 to 7 percent of their body weight.
Investing in the prevention of diabetes will help the state reduce the growth of diabetes in California. The additional Medi-Cal costs resulting from the much more expensive care required for the treatment of diabetes complications will be greatly reduced. Projected savings are estimated to be over $45 million a year.
Epinex Diagnostics, Inc., a privately held biomedical company located in Tustin, California, shares this goal by focusing on point-of-care tests that address diabetes control. It is developing a monthly G1A test for glycated albumin, which can bridge the gap between daily glucose monitoring and long-term HbA1c testing every 4 to 6 months. Epinex believes that the G1A test can play a significant role in the early diagnosis and prevention of diabetes.